human von willebrand factor

Poland

Drugs containing this active substance

  • FANHDI

    The medicinal product is used for the prevention and control of bleeding in patients with haemophilia A (congenital deficiency of coagulation factor VIII) and in patients with von Willebrand disease (VWD) when desmopressin treatment is ineffective or contraindicated. It may also be used in the treatment of acquired deficiency of human coagulation factor VIII.

    Form: powder and solvent for solution for injection and infusion

    Active substance Dosage
    human blood coagulation factor viii 500 j.m.
    human von willebrand factor 600 j.m.

    ATC: B02BD06

    Manufacturer: Instituto Grifols S.A.

  • FANHDI

    The medicine is used for the prevention and control of bleeding in patients with hemophilia A (factor VIII deficiency) and in patients with von Willebrand disease (when desmopressin treatment is ineffective or contraindicated). It may also be used in the treatment of acquired factor VIII deficiency.

    Form: powder and solvent for solution for injection and infusion

    Active substance Dosage
    human von willebrand factor 300 j.m.
    human blood coagulation factor viii 250 j.m.

    ATC: B02BD06

    Manufacturer: Instituto Grifols S.A.

  • FANHDI

    The medicinal product is used for the prevention and control of bleeding in patients with haemophilia A (deficiency of factor VIII) and in patients with von Willebrand disease (when desmopressin treatment is ineffective or contraindicated). It may also be used in the treatment of acquired factor VIII deficiency.

    Form: powder and solvent for solution for injection and infusion

    Active substance Dosage
    human blood coagulation factor viii 1000 j.m.
    human von willebrand factor 1200 j.m.

    ATC: B02BD06

    Manufacturer: Instituto Grifols S.A.